Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial

被引：0
|
作者：
Siegel, David Samuel DiCapua
Richardson, Paul Gerard Guy
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid C.
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej J.
Bahlis, Nizar J.
Song, Kevin W.
Belch, Andrew
Raje, Noopur S.
Shustik, Chaim
Lentzsch, Suzanne
Chen, Min
Zaki, Mohamed H.
Anderson, Kenneth Carl
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Washington Univ, St Louis, MO USA
[4] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[6] Mt Sinai Med Ctr, New York, NY 10029 USA
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[8] Emory Univ, Sch Med, Atlanta, GA USA
[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[10] Univ Calgary, Calgary, AB, Canada
[11] Vancouver Gen Hosp, Vancouver, BC, Canada
[12] Univ Alberta, Edmonton, AB, Canada
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
[14] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada
[15] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[16] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8588
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Spencer, Andrew
    Knop, Stefan
    Renner, Christoph
    Bahlis, Nizar J.
    Amatya, Ramesh
    Yu, Xin
    Monzini, Mara Silvia
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian J.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [22] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Lopez, Joaquin Martinez
    Chen, Christine I.
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [23] MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX)
    Siegel, David Samuel DiCapua
    Agajanian, Richy
    Gaur, Rakesh
    Karamiou, Kasra
    Kaya, Hakan
    Sturniolo, Michael
    Ricafort, Rosanna J.
    Larkins, Gall
    Srinivasan, Shankar
    Chopra, Rajosh
    Thakurta, Anjan
    Nagarwala, Yasir M.
    Kruter, Flavio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)
    Siegel, David S.
    Schiller, Gary
    Song, Kevin
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Reu, Frederic J.
    Mouro, Jorge
    Sturniolo, Michael
    Srinivasan, Shankar
    Thakurta, Anjan
    Nagarwala, Yasir
    Bahlis, Nizar J.
    BLOOD, 2015, 126 (23)
  • [25] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333
  • [26] MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis
    Sonneveld, Pieter
    Heyne, Nils
    Kueenburg, Elisabeth
    Glasmacher, Axel G.
    Kasserra, Claudia
    Rosettanl, Barbara
    Bacon, Pamela Joy
    Welsel, Katja C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Delforge, M.
    Dimopoulos, M.
    Weisel, K.
    Moreau, P.
    Lacy, M.
    Song, K.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 329 - 330
  • [28] A phase 1 b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
    Siegel, David Samuel DiCapua
    van de Donk, Niels
    Sonneveld, Pieter
    Hofmeister, Craig C.
    Bahlis, Nizar J.
    Niesvizky, Ruben
    Sternas, Lars Axel
    Peluso, Teresa
    Shah, Sheetal
    Slaughter, Ana
    Zaki, Mohamed H.
    Wang, Jianming
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
    San-Miguel, Jesus F.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
    Berenson, James R.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter
    Klein, Leonard M.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345